Melnikov Vyacheslav Y, Molitoris Bruce A
Saudi J Kidney Dis Transpl. 2008 Jul;19(4):537-44.
Acute kidney injury (AKI) represents a wide range of heterogeneous clinical conditions with a high mortality rate. Despite improvements in our understanding of the disease processes, mortality has only marginally improved and remains unacceptably high. An additional consequence of AKI is the marked acceleration of pre-existing chronic kidney disease to end-stage renal disease. A major limitation in improving outcomes of AKI has been the lack of common standards for diagnosis and severity stratification. Serum creatinine is a late marker of kidney dysfunction and injury. Presently, no available commercial test offers diagnosis, nor the ability to stratify patients by severity of injury, early in the course of disease when therapy may be beneficial. The Acute Dialysis Quality Initiative (ADQI) group proposed a standard definition and classification system for the syndrome of acute renal failure. Based on data that even small changes of serum creatinine result in increased mortality, the Acute Kidney Injury Network (AKIN) has recently proposed modified criteria. Both staging systems emphasize changes in serum creatinine and urine output. There is also potential that a number of serum and urine bio-markers developed in preclinical studies and currently being investigated and validated, will enable the early diagnosis of AKI.
急性肾损伤(AKI)代表了一系列广泛的异质性临床病症,死亡率很高。尽管我们对疾病过程的理解有所改善,但死亡率仅略有改善,仍然高得令人无法接受。AKI的另一个后果是已有的慢性肾脏病显著加速发展为终末期肾病。改善AKI治疗结果的一个主要限制是缺乏诊断和严重程度分层的通用标准。血清肌酐是肾功能障碍和损伤的晚期标志物。目前,没有任何可用的商业检测能够在疾病早期(此时治疗可能有益)提供诊断,也无法根据损伤严重程度对患者进行分层。急性透析质量倡议(ADQI)小组提出了急性肾衰竭综合征的标准定义和分类系统。基于即使血清肌酐的微小变化也会导致死亡率增加的数据,急性肾损伤网络(AKIN)最近提出了修改后的标准。这两个分期系统都强调血清肌酐和尿量的变化。在临床前研究中开发的、目前正在研究和验证的一些血清和尿液生物标志物也有可能实现AKI的早期诊断。